SGS WINS FIVE CATEGORIES IN THE 2022 CRO LEADERSHIP AWARDS
SGS has again been rewarded for its industry-leading work, receiving five 2022 CRO Leadership Awards in the categories of Capabilities, Compatibility, Expertise, Quality and Reliability. This is the sixth consecutive year that SGS has been recognized. The CRO Leadership Awards, launched by the esteemed Life Sciences Leader and Clinical Leader journals, seek to reward outstanding CROs that […]
DIGITAL PRODUCT PROTECTION MEETS SUSTAINABLE SECURITY LABELS MADE FROM PAPER
Securikett’s sustainable product range now gets a digital extension Sustainable packaging and product digitization in one step Sustainable packaging is a hot topic and Securikett was a pioneer in presenting a secure and attractive solution to meet this requirement with its “IT’S PAPER” product series. Now the Austrian company is going one step further and […]
FDA SLAPS PARTIAL HOLD ON CURIS LEUKEMIA STUDY
Curis’ phase 1/2a leukaemia study is the latest to join the club of FDA clinical holds, following the death of a trial participant. The Massachusetts-based biotech announced the partial clinical hold today, citing the FDA’s request for additional safety and efficacy data, including more information about the patient death. The trial on pause is TakeAim Leukemia, which […]
NOVARTIS UNVEILS MAJOR RE-ORG
Novartis has announced a new organizational structure and operating model, with an eye on innovation and growth — as well as targeted savings of at least $1 billion by 2024. The Swiss giant’s new “simplified structure and operational set-up” will integrate the pharmaceuticals and oncology business units, creating two separate commercial organizations with a stronger geographic focus […]
PARSORTIX SYSTEM IDENTIFIES KEY DRUG TARGETS IN CANCER METASTASIS
The study demonstrates the ability of the Parsortix system to isolate circulating tumour cells, targeting the metastatic spread of cancer. Liquid biopsy company Angle has announced the results of work undertaken in preclinical models of metastatic breast cancer (MBC), where specific genes involved in the metastatic process have been identified. The study adds to the […]
POSITIVE RESULTS FOR CEREVANCE’S PARKINSON’S DRUG
In phase 2 trials, the drug reduced ‘OFF time’ which refers to periods of the day when Parkinson’s symptoms recur despite medication Cerevance has announced positive phase 2 trial results for the company’s first-in-class, once-a-day, orally-administered compound treating Parkinson’s disease. The company is a private, clinical-stage drug discovery and development company focused on central nervous […]
MISSION THERAPEUTICS LAUNCHES CLINICAL TRIAL FOR KIDNEY DISEASE THERAPY
MTX652 has advanced through preclinical regulatory toxicology studies and is ready for a phase 1 trial Mission Therapeutics has been granted approval to take its lead USP30 deubiquitinating enzyme (DUB) inhibitor – MTX652 – into a clinical study. The mitochondrial-associated DUB removes ubiquitin, which is what damaged mitochondria are labelled with. This inhibits the degradation […]
CPHI NORTH AMERICA OPENS AS 65% OF US COMPANIES FORECAST GROWTH IN EXCESS OF 20% IN 2022
CPHI is the leading global community for pharmaceutical professionals and America’s only end-to-end pharma event Kicking off the season for pharmaceutical professionals to come together digitally (09-27 May 2022) as well as in person (17-19 May 2022). CPHI North America will be held as a SMART event, with three weeks of dedicated pharma learning and partnering. The benefit […]
Bayer pledges $300M to boost production in world’s ‘contraceptive capital’
Bayer, currently in the midst of a gung-ho cell therapy expansion in the U.S., is turning its attention back to Europe as it looks to beef up its birth control manufacturing in the world’s “contraceptive capital.” The company has designs on a €250 million ($303 million) investment for a new production plant in Turku, Finland, which […]
AZ, Pfizer/BioNTech vaccines ‘highly effective’ against Delta variant
AstraZeneca and Pfizer/BioNTech’s COVID-19 vaccines are ‘highly effective’ at protecting against the Delta (previously known as the Indian) variant, according to new real-world data from Public Health England (PHE). The analysis included 14,019 cases of the Delta variant, of which 166 were hospitalised, between 12 April and 4 June, looking at emergency hospital admissions in […]